Oxidative stress, inflammation, and cancer: How are they linked?

Free Radical Biology and Medicine

Volumn 49, Issue 11, 2010, Pages 1603-1616

  Reuter, Simone ^a   Gupta, Subash C ^a   Chaturvedi, Madan M ^a   Aggarwal, Bharat B ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Antioxidants; Cancer; Free radicals; Inflammation; NF B; Oxidative stress; Pro oxidants

Indexed keywords

ATM PROTEIN; BETA CATENIN; CELL CYCLE PROTEIN; CHEMOKINE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIN DEPENDENT KINASE 5; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FAS ANTIGEN; GROWTH FACTOR; HEME OXYGENASE 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 6; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PROTEIN P53; REACTIVE OXYGEN METABOLITE; STAT3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR NRF2; TRANSCRIPTION FACTOR SP1; UNINDEXED DRUG;

ANGIOGENESIS; CANCER INVASION; CANCER RESISTANCE; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC DISEASE; CHRONIC INFLAMMATION; GENE EXPRESSION; HUMAN; INFLAMMATION; NEOPLASM; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RADIOSENSITIVITY; REVIEW; TUMOR CELL;

ANIMALS; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; HUMANS; INFLAMMATION; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; TUMOR ESCAPE;

EID: 78049370987     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2010.09.006     Document Type: Review

References (313)

1. Durackova Z. Some current insights into oxidative stress. Physiol. Res. 2010, 59:459-469.
2. Jabs T. Reactive oxygen intermediates as mediators of programmed cell death in plants and animals. Biochem. Pharmacol. 1999, 57:231-245.
3. Poyton R.O., Ball K.A., Castello P.R. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol. Metab. 2009, 20:332-340.
4. Fridovich I. The biology of oxygen radicals. Science 1978, 201:875-880.
5. Goossens V., De Vos K., Vercammen D., Steemans M., Vancompernolle K., Fiers W., Vandenabeele P., Grooten J. Redox regulation of TNF signaling. Biofactors 1999, 10:145-156.
6. Goossens V., Grooten J., De Vos K., Fiers W. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc. Natl Acad. Sci. USA 1995, 92:8115-8119.
7. Hussain S.P., Hofseth L.J., Harris C.C. Radical causes of cancer. Nat. Rev. Cancer 2003, 3:276-285.
8. Schraufstatter I., Hyslop P.A., Jackson J.H., Cochrane C.G. Oxidant-induced DNA damage of target cells. J. Clin. Invest. 1988, 82:1040-1050.
9. Fang J., Seki T., Maeda H. Therapeutic strategies by modulating oxygen stress in cancer and inflammation. Adv. Drug Deliv. Rev. 2009, 61:290-302.
10. Khandrika L., Kumar B., Koul S., Maroni P., Koul H.K. Oxidative stress in prostate cancer. Cancer Lett. 2009, 282:125-136.
11. Visconti R., Grieco D. New insights on oxidative stress in cancer. Curr. Opin. Drug Discov. Dev. 2009, 12:240-245.
12. Briganti S., Picardo M. Antioxidant activity, lipid peroxidation and skin diseases: what's new. J. Eur. Acad. Dermatol. Venereol. 2003, 17:663-669.
13. Kinnula V.L., Crapo J.D. Superoxide dismutases in the lung and human lung diseases. Am. J. Respir. Crit. Care Med. 2003, 167:1600-1619.
14. Minelli A., Bellezza I., Conte C., Culig Z. Oxidative stress-related aging: a role for prostate cancer?. Biochim. Biophys. Acta 2009, 1795:83-91.
15. Sies H. Oxidative stress: from basic research to clinical application. Am. J. Med. 1991, 91:31S-38S.
16. Wilson J.N., Pierce J.D., Clancy R.L. Reactive oxygen species in acute respiratory distress syndrome. Heart Lung 2001, 30:370-375.
17. Dugan L.L., Quick K.L. Reactive oxygen species and aging: evolving questions. Sci. Aging Knowl. Environ. 2005, pe20; 2005.
18. Hensley K., Butterfield D.A., Hall N., Cole P., Subramaniam R., Mark R., Mattson M.P., Markesbery W.R., Harris M.E., Aksenov M., et al. Reactive oxygen species as causal agents in the neurotoxicity of the Alzheimer's disease-associated amyloid beta peptide. Ann. NY Acad. Sci. 1996, 786:120-134.
19. Multhaup G., Ruppert T., Schlicksupp A., Hesse L., Beher D., Masters C.L., Beyreuther K. Reactive oxygen species and Alzheimer's disease. Biochem. Pharmacol. 1997, 54:533-539.
20. Halliwell B. Free radicals, reactive oxygen species and human disease: a critical evaluation with special reference to atherosclerosis. Br. J. Exp. Pathol. 1989, 70:737-757.
21. Lau A.T., Wang Y., Chiu J.F. Reactive oxygen species: current knowledge and applications in cancer research and therapeutic. J. Cell. Biochem. 2008, 104:657-667.
22. Renschler M.F. The emerging role of reactive oxygen species in cancer therapy. Eur. J. Cancer 2004, 40:1934-1940.
23. Weinberg F., Chandel N.S. Reactive oxygen species-dependent signaling regulates cancer. Cell. Mol. Life Sci. 2009, 66:3663-3673.
24. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells-implications in cardiovascular disease. Braz. J. Med. Biol. Res. 2004, 37:1263-1273.
25. Yoshizumi M., Tsuchiya K., Tamaki T. Signal transduction of reactive oxygen species and mitogen-activated protein kinases in cardiovascular disease. J. Med. Invest. 2001, 48:11-24.
26. Muhammad S., Bierhaus A., Schwaninger M. Reactive oxygen species in diabetes-induced vascular damage, stroke, and Alzheimer's disease. J. Alzheimers Dis. 2009, 16:775-785.
27. Di Virgilio F. New pathways for reactive oxygen species generation in inflammation and potential novel pharmacological targets. Curr. Pharm. Des. 2004, 10:1647-1652.
28. Moulton P.J. Inflammatory joint disease: the role of cytokines, cyclooxygenases and reactive oxygen species. Br. J. Biomed. Sci. 1996, 53:317-324.
29. Bolanos J.P., Moro M.A., Lizasoain I., Almeida A. Mitochondria and reactive oxygen and nitrogen species in neurological disorders and stroke: therapeutic implications. Adv. Drug Delivery Rev. 2009, 61:1299-1315.
30. Atabek M.E., Vatansev H., Erkul I. Oxidative stress in childhood obesity. J. Pediatr. Endocrinol. Metab. 2004, 17:1063-1068.
31. Furukawa S., Fujita T., Shimabukuro M., Iwaki M., Yamada Y., Nakajima Y., Nakayama O., Makishima M., Matsuda M., Shimomura I. Increased oxidative stress in obesity and its impact on metabolic syndrome. J. Clin. Invest. 2004, 114:1752-1761.
32. Tabner B.J., Turnbull S., El-Agnaf O., Allsop D. Production of reactive oxygen species from aggregating proteins implicated in Alzheimer's disease, Parkinson's disease and other neurodegenerative diseases. Curr. Top. Med. Chem. 2001, 1:507-517.
33. Tieu K., Ischiropoulos H., Przedborski S. Nitric oxide and reactive oxygen species in Parkinson's disease. IUBMB Life 2003, 55:329-335.
34. Kamp D.W., Graceffa P., Pryor W.A., Weitzman S.A. The role of free radicals in asbestos-induced diseases. Free Radic. Biol. Med. 1992, 12:293-315.
35. Kinnula V.L., Fattman C.L., Tan R.J., Oury T.D. Oxidative stress in pulmonary fibrosis: a possible role for redox modulatory therapy. Am. J. Respir. Crit. Care Med. 2005, 172:417-422.
36. Gelderman K.A., Hultqvist M., Olsson L.M., Bauer K., Pizzolla A., Olofsson P., Holmdahl R. Rheumatoid arthritis: the role of reactive oxygen species in disease development and therapeutic strategies. Antioxid. Redox Signaling 2007, 9:1541-1567.
37. Haurani M.J., Pagano P.J. Adventitial fibroblast reactive oxygen species as autacrine and paracrine mediators of remodeling: bellwether for vascular disease?. Cardiovasc. Res. 2007, 75:679-689.
38. Jeremy J.Y., Shukla N., Muzaffar S., Handley A., Angelini G.D. Reactive oxygen species, vascular disease and cardiovascular surgery. Curr. Vasc. Pharmacol. 2004, 2:229-236.
39. Miyajima A., Nakashima J., Yoshioka K., Tachibana M., Tazaki H., Murai M. Role of reactive oxygen species in cis-dichlorodiammineplatinum-induced cytotoxicity on bladder cancer cells. Br. J. Cancer 1997, 76:206-210.
40. Salganik R.I., Albright C.D., Rodgers J., Kim J., Zeisel S.H., Sivashinskiy M.S., Van Dyke T.A. Dietary antioxidant depletion: enhancement of tumor apoptosis and inhibition of brain tumor growth in transgenic mice. Carcinogenesis 2000, 21:909-914.
41. Brown N.S., Bicknell R. Hypoxia and oxidative stress in breast cancer. Oxidative stress: its effects on the growth, metastatic potential and response to therapy of breast cancer. Breast Cancer Res. 2001, 3:323-327.
42. Sharma A., Rajappa M., Satyam A., Sharma M. Oxidant/anti-oxidant dynamics in patients with advanced cervical cancer: correlation with treatment response. Mol. Cell. Biochem. 2010, 341:65-72.
43. Oliveira C.P., Kassab P., Lopasso F.P., Souza H.P., Janiszewski M., Laurindo F.R., Iriya K., Laudanna A.A. Protective effect of ascorbic acid in experimental gastric cancer: reduction of oxidative stress. World J. Gastroenterol. 2003, 9:446-448.
44. Calvisi D.F., Ladu S., Hironaka K., Factor V.M., Thorgeirsson S.S. Vitamin E down-modulates iNOS and NADPH oxidase in c-Myc/TGF-alpha transgenic mouse model of liver cancer. J. Hepatol. 2004, 41:815-822.
45. Azad N., Rojanasakul Y., Vallyathan V. Inflammation and lung cancer: roles of reactive oxygen/nitrogen species. J. Toxicol. Environ. Health B Crit. Rev. 2008, 11:1-15.
46. Fruehauf J.P., Trapp V. Reactive oxygen species: an Achilles' heel of melanoma?. Expert Rev. Anticancer Ther. 2008, 8:1751-1757.
47. Kuku I., Aydogdu I., Bayraktar N., Kaya E., Akyol O., Erkurt M.A. Oxidant/antioxidant parameters and their relationship with medical treatment in multiple myeloma. Cell Biochem. Funct. 2005, 23:47-50.
48. Sumi D., Shinkai Y., Kumagai Y. Signal transduction pathways and transcription factors triggered by arsenic trioxide in leukemia cells. Toxicol. Appl. Pharmacol. 2010, 244:385-392.
49. van de Wetering C.I., Coleman M.C., Spitz D.R., Smith B.J., Knudson C.M. Manganese superoxide dismutase gene dosage affects chromosomal instability and tumor onset in a mouse model of T cell lymphoma. Free Radic. Biol. Med. 2008, 44:1677-1686.
50. Bahar G., Feinmesser R., Shpitzer T., Popovtzer A., Nagler R.M. Salivary analysis in oral cancer patients: DNA and protein oxidation, reactive nitrogen species, and antioxidant profile. Cancer 2007, 109:54-59.
51. Chan D.W., Liu V.W., Tsao G.S., Yao K.M., Furukawa T., Chan K.K., Ngan H.Y. Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells. Carcinogenesis 2008, 29:1742-1750.
52. Edderkaoui M., Hong P., Vaquero E.C., Lee J.K., Fischer L., Friess H., Buchler M.W., Lerch M.M., Pandol S.J., Gukovskaya A.S. Extracellular matrix stimulates reactive oxygen species production and increases pancreatic cancer cell survival through 5-lipoxygenase and NADPH oxidase. Am. J. Physiol. Gastrointest. Liver Physiol. 2005, 289:G1137-G1147.
53. Ma Q., Cavallin L.E., Yan B., Zhu S., Duran E.M., Wang H., Hale L.P., Dong C., Cesarman E., Mesri E.A., Goldschmidt-Clermont P.J. Antitumorigenesis of antioxidants in a transgenic Rac1 model of Kaposi's sarcoma. Proc. Natl Acad. Sci. USA 2009, 106:8683-8688.
54. Bartsch H., Nair J. Chronic inflammation and oxidative stress in the genesis and perpetuation of cancer: role of lipid peroxidation, DNA damage, and repair. Langenbecks Arch. Surg. 2006, 391:499-510.
55. Grivennikov S.I., Greten F.R., Karin M. Immunity, inflammation, and cancer. Cell 2010, 140:883-899.
56. Grivennikov S.I., Karin M. Inflammation and oncogenesis: a vicious connection. Curr. Opin. Genet. Dev. 2010, 20:65-71.
57. Gonda T.A., Tu S., Wang T.C. Chronic inflammation, the tumor microenvironment and carcinogenesis. Cell Cycle 2009, 8:2005-2013.
58. Garodia P., Ichikawa H., Malani N., Sethi G., Aggarwal B.B. From ancient medicine to modern medicine: Ayurvedic concepts of health and their role in inflammation and cancer. J. Soc. Integr. Oncol. 2007, 5:25-37.
59. Aggarwal B.B., Gehlot P. Inflammation and cancer: how friendly is the relationship for cancer patients?. Curr. Opin. Pharmacol. 2009, 9:351-369.
60. Schetter A.J., Heegaard N.H., Harris C.C. Inflammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010, 31:37-49.
61. Ekbom A., Helmick C., Zack M., Adami H.O. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990, 336:357-359.
62. Ekbom A., Helmick C., Zack M., Adami H.O. Ulcerative colitis and colorectal cancer: a population-based study. N Engl J. Med. 1990, 323:1228-1233.
63. Gillen C.D., Walmsley R.S., Prior P., Andrews H.A., Allan R.N. Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994, 35:1590-1592.
64. Ekbom A., McLaughlin J.K., Nyren O. Pancreatitis and the risk of pancreatic cancer. N Engl J. Med. 1993, 329:1502-1503.
65. Coussens L.M., Werb Z. Inflammation and cancer. Nature 2002, 420:860-867.
66. Kundu J.K., Surh Y.J. Inflammation: gearing the journey to cancer. Mutat. Res. 2008, 659:15-30.
67. Aggarwal B.B., Vijayalekshmi R.V., Sung B. Targeting inflammatory pathways for prevention and therapy of cancer: short-term friend, long-term foe. Clin. Cancer Res. 2009, 15:425-430.
68. Lin W.W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J. Clin. Invest. 2007, 117:1175-1183.
69. Hussain S.P., Harris C.C. Inflammation and cancer: an ancient link with novel potentials. Int. J. Cancer 2007, 121:2373-2380.
70. Federico A., Morgillo F., Tuccillo C., Ciardiello F., Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int. J. Cancer 2007, 121:2381-2386.
71. Bos J.L. ras oncogenes in human cancer: a review. Cancer Res. 1989, 49:4682-4689.
72. Sparmann A., Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004, 6:447-458.
73. Karihtala P., Soini Y. Reactive oxygen species and antioxidant mechanisms in human tissues and their relation to malignancies. APMIS 2007, 115:81-103.
74. Mates J.M., Sanchez-Jimenez F.M. Role of reactive oxygen species in apoptosis: implications for cancer therapy. Int. J. Biochem. Cell Biol. 2000, 32:157-170.
75. Ray G., Husain S.A. Oxidants, antioxidants and carcinogenesis. Indian J. Exp. Biol. 2002, 40:1213-1232.
76. Valko M., Izakovic M., Mazur M., Rhodes C.J., Telser J. Role of oxygen radicals in DNA damage and cancer incidence. Mol. Cell. Biochem. 2004, 266:37-56.
77. Marnett L.J. Oxyradicals and DNA damage. Carcinogenesis 2000, 21:361-370.
78. Wiseman H., Halliwell B. Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer. Biochem. J. 1996, 313(Pt 1):17-29.
79. Malins D.C., Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res. 1991, 51:5430-5432.
80. Matsui A., Ikeda T., Enomoto K., Hosoda K., Nakashima H., Omae K., Watanabe M., Hibi T., Kitajima M. Increased formation of oxidative DNA damage, 8-hydroxy-2'-deoxyguanosine, in human breast cancer tissue and its relationship to GSTP1 and COMT genotypes. Cancer Lett. 2000, 151:87-95.
81. Musarrat J., Arezina-Wilson J., Wani A.A. Prognostic and aetiological relevance of 8-hydroxyguanosine in human breast carcinogenesis. Eur. J. Cancer 1996, 32A:1209-1214.
82. Nathan C., Xie Q.W. Regulation of biosynthesis of nitric oxide. J. Biol. Chem. 1994, 269:13725-13728.
83. Davis K.L., Martin E., Turko I.V., Murad F. Novel effects of nitric oxide. Annu. Rev. Pharmacol. Toxicol. 2001, 41:203-236.
84. Moncada S., Higgs A. The l-arginine-nitric oxide pathway. N Engl J. Med. 1993, 329:2002-2012.
85. Lowenstein C.J., Padalko E. iNOS (NOS2) at a glance. J. Cell Sci. 2004, 117:2865-2867.
86. Xie Q.W., Kashiwabara Y., Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J. Biol. Chem. 1994, 269:4705-4708.
87. Zhang Y., Qi H., Taylor R., Xu W., Liu L.F., Jin S. The role of autophagy in mitochondria maintenance: characterization of mitochondrial functions in autophagy-deficient S. cerevisiae strains. Autophagy 2007, 3:337-346.
88. Mathew R., Karp C.M., Beaudoin B., Vuong N., Chen G., Chen H.Y., Bray K., Reddy A., Bhanot G., Gelinas C., Dipaola R.S., Karantza-Wadsworth V., White E. Autophagy suppresses tumorigenesis through elimination of p62. Cell 2009, 137:1062-1075.
89. Pompella A., Visvikis A., Paolicchi A., De Tata V., Casini A.F. The changing faces of glutathione, a cellular protagonist. Biochem. Pharmacol. 2003, 66:1499-1503.
90. Valko M., Leibfritz D., Moncol J., Cronin M.T., Mazur M., Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int. J. Biochem. Cell Biol. 2007, 39:44-84.
91. Calvert P., Yao K.S., Hamilton T.C., O'Dwyer P.J. Clinical studies of reversal of drug resistance based on glutathione. Chem. Biol. Interact. 1998, 111-112:213-224.
92. Balendiran G.K., Dabur R., Fraser D. The role of glutathione in cancer. Cell Biochem. Funct. 2004, 22:343-352.
93. Estrela J.M., Ortega A., Obrador E. Glutathione in cancer biology and therapy. Crit. Rev. Clin. Lab. Sci. 2006, 43:143-181.
94. McCord J.M., Fridovich I. Superoxide dismutase: an enzymic function for erythrocuprein (hemocuprein). J. Biol. Chem. 1969, 244:6049-6055.
95. Meira L.B., Bugni J.M., Green S.L., Lee C.W., Pang B., Borenshtein D., Rickman B.H., Rogers A.B., Moroski-Erkul C.A., McFaline J.L., Schauer D.B., Dedon P.C., Fox J.G., Samson L.D. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J. Clin. Invest. 2008, 118:2516-2525.
96. Das P.M., Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22:4632-4642.
97. Fleisher A.S., Esteller M., Harpaz N., Leytin A., Rashid A., Xu Y., Liang J., Stine O.C., Yin J., Zou T.T., Abraham J.M., Kong D., Wilson K.T., James S.P., Herman J.G., Meltzer S.J. Microsatellite instability in inflammatory bowel disease-associated neoplastic lesions is associated with hypermethylation and diminished expression of the DNA mismatch repair gene, hMLH1. Cancer Res. 2000, 60:4864-4868.
98. Park J.H., Mangal D., Frey A.J., Harvey R.G., Blair I.A., Penning T.M. Aryl hydrocarbon receptor facilitates DNA strand breaks and 8-oxo-2'-deoxyguanosine formation by the aldo-keto reductase product benzo[a]pyrene-7, 8-dione. J. Biol. Chem. 2009, 284:29725-29734.
99. Amstad P., Crawford D., Muehlematter D., Zbinden I., Larsson R., Cerutti P. Oxidants stress induces the proto-oncogenes, C-fos and C-myc in mouse epidermal cells. Bull. Cancer 1990, 77:501-502.
100. Amstad P.A., Krupitza G., Cerutti P.A. Mechanism of c-fos induction by active oxygen. Cancer Res. 1992, 52:3952-3960.
101. Alexander A., Cai S.L., Kim J., Nanez A., Sahin M., MacLean K.H., Inoki K., Guan K.L., Shen J., Person M.D., Kusewitt D., Mills G.B., Kastan M.B., Walker C.L. ATM signals to TSC2 in the cytoplasm to regulate mTORC1 in response to ROS. Proc. Natl Acad. Sci. USA 2010, 107:4153-4158.
102. Li L., Wang J., Ye R.D., Shi G., Jin H., Tang X., Yi J. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J. Cell. Physiol. 2008, 217:486-493.
103. Barlow C.A., Kitiphongspattana K., Siddiqui N., Roe M.W., Mossman B.T., Lounsbury K.M. Protein kinase A-mediated CREB phosphorylation is an oxidant-induced survival pathway in alveolar type II cells. Apoptosis 2008, 13:681-692.
104. Sun K.H., de Pablo Y., Vincent F., Shah K. Deregulated Cdk5 promotes oxidative stress and mitochondrial dysfunction. J. Neurochem. 2008, 107:265-278.
105. Burch P.M., Heintz N.H. Redox regulation of cell-cycle re-entry: cyclin D1 as a primary target for the mitogenic effects of reactive oxygen and nitrogen species. Antioxid. Redox Signaling 2005, 7:741-751.
106. Franco R., Schoneveld O., Georgakilas A.G., Panayiotidis M.I. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008, 266:6-11.
107. Maynard S., Schurman S.H., Harboe C., de Souza-Pinto N.C., Bohr V.A. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis 2009, 30:2-10.
108. Goldkorn T., Ravid T., Khan E.M. Life and death decisions: ceramide generation and EGF receptor trafficking are modulated by oxidative stress. Antioxid. Redox Signaling 2005, 7:119-128.
109. Wartenberg M., Schallenberg M., Hescheler J., Sauer H. Reactive oxygen species-mediated regulation of eNOS and iNOS expression in multicellular prostate tumor spheroids. Int. J. Cancer 2003, 104:274-282.
110. McCubrey J.A., Lahair M.M., Franklin R.A. Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxid. Redox Signaling 2006, 8:1775-1789.
111. Kwon D., Choi C., Lee J., Kim K.O., Kim J.D., Kim S.J., Choi I.H. Hydrogen peroxide triggers the expression of Fas/FasL in astrocytoma cell lines and augments apoptosis. J. Neuroimmunol. 2001, 113:1-9.
112. Goto T., Takano M. Transcriptional role of FOXO1 in drug resistance through antioxidant defense systems. Adv. Exp. Med. Biol. 2009, 665:171-179.
113. Kietzmann T., Gorlach A. Reactive oxygen species in the control of hypoxia-inducible factor-mediated gene expression. Semin. Cell Dev. Biol. 2005, 16:474-486.
114. Ryter S.W., Choi A.M. Heme oxygenase-1: redox regulation of a stress protein in lung and cell culture models. Antioxid. Redox Signaling 2005, 7:80-91.
115. Kuga S., Otsuka T., Niiro H., Nunoi H., Nemoto Y., Nakano T., Ogo T., Umei T., Niho Y. Suppression of superoxide anion production by interleukin-10 is accompanied by a downregulation of the genes for subunit proteins of NADPH oxidase. Exp. Hematol. 1996, 24:151-157.
116. Svineng G., Ravuri C., Rikardsen O., Huseby N.E., Winberg J.O. The role of reactive oxygen species in integrin and matrix metalloproteinase expression and function. Connect. Tissue Res. 2008, 49:197-202.
117. Hellstrand K., Hermodsson S., Naredi P., Mellqvist U.H., Brune M. Histamine and cytokine therapy. Acta Oncol. 1998, 37:347-353.
118. Simon A.R., Rai U., Fanburg B.L., Cochran B.H. Activation of the JAK-STAT pathway by reactive oxygen species. Am. J. Physiol. 1998, 275:C1640-C1652.
119. Lo Y.Y., Wong J.M., Cruz T.F. Reactive oxygen species mediate cytokine activation of c-Jun NH2-terminal kinases. J. Biol. Chem. 1996, 271:15703-15707.
120. Skinner A.M., Turker M.S. Oxidative mutagenesis, mismatch repair, and aging. Sci. Aging Knowledge Environ. 2005, re3; 2005.
121. Byun Y.J., Kim S.K., Kim Y.M., Chae G.T., Jeong S.W., Lee S.B. Hydrogen peroxide induces autophagic cell death in C6 glioma cells via BNIP3-mediated suppression of the mTOR pathway. Neurosci. Lett. 2009, 461:131-135.
122. Venugopal R., Jaiswal A.K. Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase 1 gene. Proc. Natl Acad. Sci. USA 1996, 93:14960-14965.
123. Gloire G., Legrand-Poels S., Piette J. NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 2006, 72:1493-1505.
124. Itoh K., Chiba T., Takahashi S., Ishii T., Igarashi K., Katoh Y., Oyake T., Hayashi N., Satoh K., Hatayama I., Yamamoto M., Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem. Biophys. Res. Commun. 1997, 236:313-322.
125. Clerkin J.S., Naughton R., Quiney C., Cotter T.G. Mechanisms of ROS modulated cell survival during carcinogenesis. Cancer Lett. 2008, 266:30-36.
126. Torres M., Forman H.J. Redox signaling and the MAP kinase pathways. Biofactors 2003, 17:287-296.
127. Han E.S., Muller F.L., Perez V.I., Qi W., Liang H., Xi L., Fu C., Doyle E., Hickey M., Cornell J., Epstein C.J., Roberts L.J., Van Remmen H., Richardson A. The in vivo gene expression signature of oxidative stress. Physiol. Genomics 2008, 34:112-126.
128. Tishler R.B., Calderwood S.K., Coleman C.N., Price B.D. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents. Cancer Res. 1993, 53:2212-2216.
129. Kanthasamy A.G., Kitazawa M., Kanthasamy A., Anantharam V. Role of proteolytic activation of protein kinase Cdelta in oxidative stress-induced apoptosis. Antioxid. Redox Signaling 2003, 5:609-620.
130. Rusyn I., Rose M.L., Bojes H.K., Thurman R.G. Novel role of oxidants in the molecular mechanism of action of peroxisome proliferators. Antioxid. Redox Signaling 2000, 2:607-621.
131. Cao J., Schulte J., Knight A., Leslie N.R., Zagozdzon A., Bronson R., Manevich Y., Beeson C., Neumann C.A. Prdx1 inhibits tumorigenesis via regulating PTEN/AKT activity. EMBO J. 2009, 28:1505-1517.
132. Chiarugi P. PTPs versus PTKs: the redox side of the coin. Free Radic. Res. 2005, 39:353-364.
133. Ammendola R., Mesuraca M., Russo T., Cimino F. The DNA-binding efficiency of Sp1 is affected by redox changes. Eur. J. Biochem. 1994, 225:483-489.
134. Ushio-Fukai M., Alexander R.W. Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase. Mol. Cell. Biochem. 2004, 264:85-97.
135. Funato Y., Michiue T., Asashima M., Miki H. The thioredoxin-related redox-regulating protein nucleoredoxin inhibits Wnt-beta-catenin signalling through dishevelled. Nat. Cell Biol. 2006, 8:501-508.
136. Korswagen H.C. Regulation of the Wnt/beta-catenin pathway by redox signaling. Dev. Cell 2006, 10:687-688.
137. Droge W. Free radicals in the physiological control of cell function. Physiol. Rev. 2002, 82:47-95.
138. Kerr L.D., Inoue J., Verma I.M. Signal transduction: the nuclear target. Curr. Opin. Cell Biol. 1992, 4:496-501.
139. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell Biol. 2002, 4:E131-E136.
140. Gorlach A., Kietzmann T. Superoxide and derived reactive oxygen species in the regulation of hypoxia-inducible factors. Methods Enzymol. 2007, 435:421-446.
141. Liu B., Chen Y. St Clair, D. K. ROS and p53: a versatile partnership. Free Radic. Biol. Med. 2008, 44:1529-1535.
142. Mantovani A. Cancer: inflammation by remote control. Nature 2005, 435:752-753.
143. Ames B.N., Gold L.S. Animal cancer tests and cancer prevention. J. Natl Cancer Inst. Monogr. 1992, 12:125-132.
144. Guyton K.Z., Kensler T.W. Oxidative mechanisms in carcinogenesis. Br. Med. Bull. 1993, 49:523-544.
145. Schulte-Hermann R., Timmermann-Trosiener I., Barthel G., Bursch W. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res. 1990, 50:5127-5135.
146. Klaunig J.E., Xu Y., Isenberg J.S., Bachowski S., Kolaja K.L., Jiang J., Stevenson D.E., Walborg E.F. The role of oxidative stress in chemical carcinogenesis. Environ. Health Perspect. 1998, 106(Suppl. 1):289-295.
147. Oshima H., B., H. Chronic infectious and inflammation process as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat. Res. 1994, 305:253-264.
148. Rosin M.P., Saad el Din Zaki S., Ward A.J., Anwar W.A. Involvement of inflammatory reactions and elevated cell proliferation in the development of bladder cancer in schistosomiasis patients. Mutat. Res. 1994, 305:283-292.
149. Weitzman S.A., Gordon L.I. Inflammation and cancer: role of phagocyte-generated oxidants in carcinogenesis. Blood 1990, 76:655-663.
150. Frenkel K. Carcinogen-mediated oxidant formation and oxidative DNA damage. Pharmacol. Ther. 1992, 53:127-166.
151. Shacter E., Beecham E.J., Covey J.M., Kohn K.W., Potter M. Activated neutrophils induce prolonged DNA damage in neighboring cells. Carcinogenesis 1988, 9:2297-2304.
152. Wei H., Frenkel K. Suppression of tumor promoter-induced oxidative events and DNA damage in vivo by sarcophytol A: a possible mechanism of antipromotion. Cancer Res. 1992, 52:2298-2303.
153. Hattori-Nakakuki Y., Nishigori C., Okamoto K., Imamura S., Hiai H., Toyokuni S. Formation of 8-hydroxy-2'-deoxyguanosine in epidermis of hairless mice exposed to near-UV. Biochem. Biophys. Res. Commun. 1994, 201:1132-1139.
154. Weitberg A.B. Effect of combinations of antioxidants on phagocyte-induced sister-chromatid exchanges. Mutat. Res. 1989, 224:1-4.
155. Yamashina K., Miller B.E., Heppner G.H. Macrophage-mediated induction of drug-resistant variants in a mouse mammary tumor cell line. Cancer Res. 1986, 46:2396-2401.
156. Dizdaroglu M., Olinski R., Doroshow J.H., Akman S.A. Modification of DNA bases in chromatin of intact target human cells by activated human polymorphonuclear leukocytes. Cancer Res. 1993, 53:1269-1272.
157. Trush M.A., Twerdok L.E., Esterline R.L. Comparison of oxidant activities and the activation of benzo(a)pyrene-7, 8-dihydrodiol by polymorphonuclear leucocytes from human, rat and mouse. Xenobiotica 1990, 20:925-932.
158. Trush M.A., Kensler T.W. An overview of the relationship between oxidative stress and chemical carcinogenesis. Free Radic. Biol. Med. 1991, 10:201-209.
159. Jackson A.L., Loeb L.A. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res. 2001, 477:7-21.
160. Storz P. Reactive oxygen species in tumor progression. Front. Biosci. 2005, 10:1881-1896.
161. Kroncke K.D. Nitrosative stress and transcription. Biol. Chem. 2003, 384:1365-1377.
162. Cerutti P.A., Trump B.F. Inflammation and oxidative stress in carcinogenesis. Cancer Cells 1991, 3:1-7.
163. Cerutti P.A. Prooxidant states and tumor promotion. Science 1985, 227:375-381.
164. Slaga T.J., Klein-Szanto A.J., Triplett L.L., Yotti L.P., Trosko K.E. Skin tumor-promoting activity of benzoyl peroxide, a widely used free radical-generating compound. Science 1981, 213:1023-1025.
165. Kamata T. Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci. 2009, 100:1382-1388.
166. Los M., Maddika S., Erb B., Schulze-Osthoff K. Switching Akt: from survival signaling to deadly response. Bioessays 2009, 31:492-495.
167. Azad M.B., Chen Y., Gibson S.B. Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid. Redox Signaling 2009, 11:777-790.
168. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
169. Plas D.R., Thompson C.B. Akt-dependent transformation: there is more to growth than just surviving. Oncogene 2005, 24:7435-7442.
170. Muller J.M., Cahill M.A., Rupec R.A., Baeuerle P.A., Nordheim A. Antioxidants as well as oxidants activate c-fos via Ras-dependent activation of extracellular-signal-regulated kinase 2 and Elk-1. Eur. J. Biochem. 1997, 244:45-52.
171. Pennington J.D., Wang T.J., Nguyen P., Sun L., Bisht K., Smart D., Gius D. Redox-sensitive signaling factors as novel molecular targets for cancer therapy. Drug Resist. Update 2005, 8:322-330.
172. Xia Z., Dickens M., Raingeaud J., Davis R.J., Greenberg M.E. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995, 270:1326-1331.
173. Chang L., Karin M. Mammalian MAP kinase signalling cascades. Nature 2001, 410:37-40.
174. Gupta S., Campbell D., Derijard B., Davis R.J. Transcription factor ATF2 regulation by the JNK signal transduction pathway. Science 1995, 267:389-393.
175. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases. J. Biol. Chem. 1995, 270:16483-16486.
176. Baldwin A.S. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu. Rev. Immunol. 1996, 14:649-683.
177. Baeuerle P.A., Lenardo M., Pierce J.W., Baltimore D. Phorbol-ester-induced activation of the NF-kappa B transcription factor involves dissociation of an apparently cytoplasmic NF-kappa B/inhibitor complex. Cold Spring Harb. Symp. Quant. Biol. 1988, 53(Pt 2):789-798.
178. Li N., Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc. Natl Acad. Sci. USA 1998, 95:13012-13017.
179. Rath P.C., Aggarwal B.B. Antiproliferative effects of IFN-alpha correlate with the downregulation of nuclear factor-kappa B in human Burkitt lymphoma Daudi cells. J. Interferon Cytokine Res. 2001, 21:523-528.
180. Bours V., Dejardin E., Goujon-Letawe F., Merville M.P., Castronovo V. The NF-kappa B transcription factor and cancer: high expression of NF-kappa B- and I kappa B-related proteins in tumor cell lines. Biochem. Pharmacol. 1994, 47:145-149.
181. Delhalle S., Deregowski V., Benoit V., Merville M.P., Bours V. NF-kappaB-dependent MnSOD expression protects adenocarcinoma cells from TNF-alpha-induced apoptosis. Oncogene 2002, 21:3917-3924.
182. Pham C.G., Bubici C., Zazzeroni F., Papa S., Jones J., Alvarez K., Jayawardena S., De Smaele E., Cong R., Beaumont C., Torti F.M., Torti S.V., Franzoso G. Ferritin heavy chain upregulation by NF-kappaB inhibits TNFalpha-induced apoptosis by suppressing reactive oxygen species. Cell 2004, 119:529-542.
183. Schulze-Osthoff K., Ferrari D., Los M., Wesselborg S., Peter M.E. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998, 254:439-459.
184. Giri D.K., Aggarwal B.B. Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells: autocrine role of tumor necrosis factor and reactive oxygen intermediates. J. Biol. Chem. 1998, 273:14008-14014.
185. Nomura M., Ma W., Chen N., Bode A.M., Dong Z. Inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced NF-kappaB activation by tea polyphenols, (-)-epigallocatechin gallate and theaflavins. Carcinogenesis 2000, 21:1885-1890.
186. Schulze-Osthoff K., Bauer M.K., Vogt M., Wesselborg S. Oxidative stress and signal transduction. Int. J. Vitam. Nutr. Res. 1997, 67:336-342.
187. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic. Biol. Med. 1990, 8:583-599.
188. Schmidt K.N., Amstad P., Cerutti P., Baeuerle P.A. The roles of hydrogen peroxide and superoxide as messengers in the activation of transcription factor NF-kappa B. Chem. Biol. 1995, 2:13-22.
189. Kass G.E., Duddy S.K., Orrenius S. Activation of hepatocyte protein kinase C by redox-cycling quinones. Biochem. J. 1989, 260:499-507.
190. Larsson R., Cerutti P. Translocation and enhancement of phosphotransferase activity of protein kinase C following exposure in mouse epidermal cells to oxidants. Cancer Res. 1989, 49:5627-5632.
191. Konishi H., Matsuzaki H., Tanaka M., Takemura Y., Kuroda S., Ono Y., Kikkawa U. Activation of protein kinase B (Akt/RAC-protein kinase) by cellular stress and its association with heat shock protein Hsp27. FEBS Lett. 1997, 410:493-498.
192. D'Souza R.J., Phillips H.M., Jones P.W., Strange R.C., Aber G.M. Interactions of hydrogen peroxide with interleukin-6 and platelet-derived growth factor in determining mesangial cell growth: effect of repeated oxidant stress. Clin. Sci. (London) 1993, 85:747-751.
193. Alliangana D.M. Effects of beta-carotene, flavonoid quercitin and quinacrine on cell proliferation and lipid peroxidation breakdown products in BHK-21 cells. East Afr. Med. J. 1996, 73:752-757.
194. Chang M.C., Chan C.P., Wang Y.J., Lee P.H., Chen L.I., Tsai Y.L., Lin B.R., Wang Y.L., Jeng J.H. Induction of necrosis and apoptosis to KB cancer cells by sanguinarine is associated with reactive oxygen species production and mitochondrial membrane depolarization. Toxicol. Appl. Pharmacol. 2007, 218:143-151.
195. Dypbukt J.M., Ankarcrona M., Burkitt M., Sjoholm A., Strom K., Orrenius S., Nicotera P. Different prooxidant levels stimulate growth, trigger apoptosis, or produce necrosis of insulin-secreting RINm5F cells: the role of intracellular polyamines. J. Biol. Chem. 1994, 269:30553-30560.
196. Halliwell B. Oxidative stress and cancer: have we moved forward?. Biochem. J. 2007, 401:1-11.
197. Kundu N., Zhang S., Fulton A.M. Sublethal oxidative stress inhibits tumor cell adhesion and enhances experimental metastasis of murine mammary carcinoma. Clin. Exp. Metastasis 1995, 13:16-22.
198. Roebuck K.A. Oxidant stress regulation of IL-8 and ICAM-1 gene expression: differential activation and binding of the transcription factors AP-1 and NF-kappaB. Int. J. Mol. Med. 1999, 4:223-230.
199. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 1999, 13:781-792.
200. Mori K., Shibanuma M., Nose K. Invasive potential induced under long-term oxidative stress in mammary epithelial cells. Cancer Res. 2004, 64:7464-7472.
201. Nelson A.R., Fingleton B., Rothenberg M.L., Matrisian L.M. Matrix metalloproteinases: biologic activity and clinical implications. J. Clin. Oncol. 2000, 18:1135-1149.
202. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro: implications for atherosclerotic plaque stability. J. Clin. Invest. 1996, 98:2572-2579.
203. Nelson K.K., Melendez J.A. Mitochondrial redox control of matrix metalloproteinases. Free Radic. Biol. Med. 2004, 37:768-784.
204. Yoon S.O., Park S.J., Yoon S.Y., Yun C.H., Chung A.S. Sustained production of H2O2 activates pro-matrix metalloproteinase-2 through receptor tyrosine kinases/phosphatidylinositol 3-kinase/NF-kappa B pathway. J. Biol. Chem. 2002, 277:30271-30282.
205. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
206. Kollmar O., Rupertus K., Scheuer C., Junker B., Tilton B., Schilling M.K., Menger M.D. Stromal cell-derived factor-1 promotes cell migration and tumor growth of colorectal metastasis. Neoplasia 2007, 9:862-870.
207. Owen J.D., Strieter R., Burdick M., Haghnegahdar H., Nanney L., Shattuck-Brandt R., Richmond A. Enhanced tumor-forming capacity for immortalized melanocytes expressing melanoma growth stimulatory activity/growth-regulated cytokine beta and gamma proteins. Int. J. Cancer 1997, 73:94-103.
208. Yuecheng Y., Xiaoyan X. Stromal-cell derived factor-1 regulates epithelial ovarian cancer cell invasion by activating matrix metalloproteinase-9 and matrix metalloproteinase-2. Eur. J. Cancer Prev. 2007, 16:430-435.
209. Lu H., Ouyang W., Huang C. Inflammation, a key event in cancer development. Mol. Cancer Res. 2006, 4:221-233.
210. Wen D.S., Zhu X.L., Guan S.M., Wu Y.M., Yu L.L., Wu J.Z. Silencing of CXCR4 inhibits the proliferation, adhesion, chemotaxis and invasion of salivary gland mucoepidermoid carcinoma Mc3 cells in vitro. Oral Oncol. 2008, 44:545-554.
211. van Wetering S., van Buul J.D., Quik S., Mul F.P., Anthony E.C., ten Klooster J.P., Collard J.G., Hordijk P.L. Reactive oxygen species mediate Rac-induced loss of cell-cell adhesion in primary human endothelial cells. J. Cell Sci. 2002, 115:1837-1846.
212. Diers A.R., Dranka B.P., Ricart K.C., Oh J.Y., Johnson M.S., Zhou F., Pallero M.A., Bodenstine T.M., Murphy-Ullrich J.E., Welch D.R., Landar A. Modulation of mammary cancer cell migration by 15-deoxy-delta(12,14)-prostaglandin J(2): implications for anti-metastatic therapy. Biochem. J. 2010, 430:69-78.
213. Stamatakis K., Perez-Sala D. Prostanoids with cyclopentenone structure as tools for the characterization of electrophilic lipid-protein interactomes. Ann. NY Acad. Sci. 2006, 1091:548-570.
214. Stamatakis K., Sanchez-Gomez F.J., Perez-Sala D. Identification of novel protein targets for modification by 15-deoxy-Delta12, 14-prostaglandin J2 in mesangial cells reveals multiple interactions with the cytoskeleton. J. Am. Soc. Nephrol. 2006, 17:89-98.
215. Aldini G., Carini M., Vistoli G., Shibata T., Kusano Y., Gamberoni L., Dalle-Donne I., Milzani A., Uchida K. Identification of actin as a 15-deoxy-Delta12, 14-prostaglandin J2 target in neuroblastoma cells: mass spectrometric, computational, and functional approaches to investigate the effect on cytoskeletal derangement. Biochemistry 2007, 46:2707-2718.
216. Cheng G.C., Schulze P.C., Lee R.T., Sylvan J., Zetter B.R., Huang H. Oxidative stress and thioredoxin-interacting protein promote intravasation of melanoma cells. Exp. Cell Res. 2004, 300:297-307.
217. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 1985, 43:175-203.
218. Aruoma O.I., Halliwell B. Superoxide-dependent and ascorbate-dependent formation of hydroxyl radicals from hydrogen peroxide in the presence of iron: are lactoferrin and transferrin promoters of hydroxyl-radical generation?. Biochem. J. 1987, 241:273-278.
219. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64:327-336.
220. North S., Moenner M., Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett. 2005, 218:1-14.
221. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
222. Chandel N.S., Maltepe E., Goldwasser E., Mathieu C.E., Simon M.C., Schumacker P.T. Mitochondrial reactive oxygen species trigger hypoxia-induced transcription. Proc. Natl Acad. Sci. USA 1998, 95:11715-11720.
223. Mazure N.M., Chen E.Y., Yeh P., Laderoute K.R., Giaccia A.J. Oncogenic transformation and hypoxia synergistically act to modulate vascular endothelial growth factor expression. Cancer Res. 1996, 56:3436-3440.
224. Okada F., Rak J.W., Croix B.S., Lieubeau B., Kaya M., Roncari L., Shirasawa S., Sasazuki T., Kerbel R.S. Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. Proc. Natl Acad. Sci. USA 1998, 95:3609-3614.
225. Van Meir E.G., Polverini P.J., Chazin V.R., Su Huang H.J., de Tribolet N., Cavenee W.K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet. 1994, 8:171-176.
226. Longo R., Sarmiento R., Fanelli M., Capaccetti B., Gattuso D., Gasparini G. Anti-angiogenic therapy: rationale, challenges and clinical studies. Angiogenesis 2002, 5:237-256.
227. Alon T., Hemo I., Itin A., Pe'er J., Stone J., Keshet E. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat. Med. 1995, 1:1024-1028.
228. Eatock M.M., Schatzlein A., Kaye S.B. Tumour vasculature as a target for anticancer therapy. Cancer Treat. Rev. 2000, 26:191-204.
229. Monte M., Davel L.E., Sacerdote de Lustig E. Hydrogen peroxide is involved in lymphocyte activation mechanisms to induce angiogenesis. Eur. J. Cancer 1997, 33:676-682.
230. Monte M., Davel L.E., de Lustig E.S. Inhibition of lymphocyte-induced angiogenesis by free radical scavengers. Free Radic. Biol. Med. 1994, 17:259-266.
231. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2:38-47.
232. Hockel M., Schlenger K., Hockel S., Vaupel P. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res. 1999, 59:4525-4528.
233. Hockel M., Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl Cancer Inst. 2001, 93:266-276.
234. Roessner A., Kuester D., Malfertheiner P., Schneider-Stock R. Oxidative stress in ulcerative colitis-associated carcinogenesis. Pathol. Res. Pract. 2008, 204:511-524.
235. Martey C.A., Pollock S.J., Turner C.K., O'Reilly K.M., Baglole C.J., Phipps R.P., Sime P.J. Cigarette smoke induces cyclooxygenase-2 and microsomal prostaglandin E2 synthase in human lung fibroblasts: implications for lung inflammation and cancer. Am. J. Physiol. Lung Cell. Mol. Physiol. 2004, 287:L981-L991.
236. Garcea G., Dennison A.R., Steward W.P., Berry D.P. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology 2005, 5:514-529.
237. Murphy S.J., Anderson L.A., Johnston B.T., Fitzpatrick D.A., Watson P.R., Monaghan P., Murray L.J. Have patients with esophagitis got an increased risk of adenocarcinoma? Results from a population-based study. World J. Gastroenterol. 2005, 11:7290-7295.
238. de Visser K.E., Jonkers J. Towards understanding the role of cancer-associated inflammation in chemoresistance. Curr. Pharm. Des. 2009, 15:1844-1853.
239. Borst P., Jonkers J., Rottenberg S. What makes tumors multidrug resistant?. Cell Cycle 2007, 6:2782-2787.
240. Schmitt C.A., Fridman J.S., Yang M., Lee S., Baranov E., Hoffman R.M., Lowe S.W. A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 2002, 109:335-346.
241. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug Discov. 2006, 5:219-234.
242. Voorzanger-Rousselot N., Alberti L., Blay J.Y. CD40L induces multidrug resistance to apoptosis in breast carcinoma and lymphoma cells through caspase independent and dependent pathways. BMC Cancer 2006, 6:75.
243. Ho E.A., Piquette-Miller M. Regulation of multidrug resistance by pro-inflammatory cytokines. Curr. Cancer Drug Targets 2006, 6:295-311.
244. Petrovic V., Teng S., Piquette-Miller M. Regulation of drug transporters during infection and inflammation. Mol. Interv. 2007, 7:99-111.
245. Hartmann G., Vassileva V., Piquette-Miller M. Impact of endotoxin-induced changes in P-glycoprotein expression on disposition of doxorubicin in mice. Drug Metab. Dispos. 2005, 33:820-828.
246. Blokzijl H., van Steenpaal A., Vander Borght S., Bok L.I., Libbrecht L., Tamminga M., Geuken M., Roskams T.A., Dijkstra G., Moshage H., Jansen P.L., Faber K.N. Up-regulation and cytoprotective role of epithelial multidrug resistance-associated protein 1 in inflammatory bowel disease. J. Biol. Chem. 2008, 283:35630-35637.
247. Bottero V., Busuttil V., Loubat A., Magne N., Fischel J.L., Milano G., Peyron J.F. Activation of nuclear factor kappaB through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 2001, 61:7785-7791.
248. Das K.C., White C.W. Activation of NF-kappaB by antineoplastic agents: role of protein kinase C. J. Biol. Chem. 1997, 272:14914-14920.
249. Piret B., Piette J. Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells. Nucleic Acids Res. 1996, 24:4242-4248.
250. Ahn K.S., Sethi G., Aggarwal B.B. Nuclear factor-kappa B: from clone to clinic. Curr. Mol. Med. 2007, 7:619-637.
251. Raju U., Gumin G.J., Noel F., Tofilon P.J. IkappaBalpha degradation is not a requirement for the X-ray-induced activation of nuclear factor kappaB in normal rat astrocytes and human brain tumour cells. Int. J. Radiat. Biol. 1998, 74:617-624.
252. Chen R., Alvero A.B., Silasi D.A., Kelly M.G., Fest S., Visintin I., Leiser A., Schwartz P.E., Rutherford T., Mor G. Regulation of IKKbeta by miR-199a affects NF-kappaB activity in ovarian cancer cells. Oncogene 2008, 27:4712-4723.
253. Kelly M.G., Alvero A.B., Chen R., Silasi D.A., Abrahams V.M., Chan S., Visintin I., Rutherford T., Mor G. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 2006, 66:3859-3868.
254. Braunstein S., Formenti S.C., Schneider R.J. Acquisition of stable inducible up-regulation of nuclear factor-kappaB by tumor necrosis factor exposure confers increased radiation resistance without increased transformation in breast cancer cells. Mol. Cancer Res. 2008, 6:78-88.
255. Douglas K.T. Mechanism of action of glutathione-dependent enzymes. Adv. Enzymol. Relat. Areas Mol. Biol. 1987, 59:103-167.
256. Sau A., Pellizzari Tregno F., Valentino F., Federici G., Caccuri A.M. Glutathione transferases and development of new principles to overcome drug resistance. Arch. Biochem. Biophys. 2010, 500:116-122.
257. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45:51-88.
258. Lau A., Villeneuve N.F., Sun Z., Wong P.K., Zhang D.D. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008, 58:262-270.
259. Wang X.J., Sun Z., Villeneuve N.F., Zhang S., Zhao F., Li Y., Chen W., Yi X., Zheng W., Wondrak G.T., Wong P.K., Zhang D.D. Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2. Carcinogenesis 2008, 29:1235-1243.
260. Cho J.M., Manandhar S., Lee H.R., Park H.M., Kwak M.K. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance. Cancer Lett. 2008, 260:96-108.
261. Padmanabhan B., Tong K.I., Ohta T., Nakamura Y., Scharlock M., Ohtsuji M., Kang M.I., Kobayashi A., Yokoyama S., Yamamoto M. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 2006, 21:689-700.
262. Singh A., Misra V., Thimmulappa R.K., Lee H., Ames S., Hoque M.O., Herman J.G., Baylin S.B., Sidransky D., Gabrielson E., Brock M.V., Biswal S. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006, 3:e420.
263. Jozkowicz A., Was H., Dulak J. Heme oxygenase-1 in tumors: is it a false friend?. Antioxid. Redox Signaling 2007, 9:2099-2117.
264. Brigelius-Flohe R. Selenium compounds and selenoproteins in cancer. Chem. Biodivers. 2008, 5:389-395.
265. Kim J.H., Bogner P.N., Ramnath N., Park Y., Yu J., Park Y.M. Elevated peroxiredoxin 1, but not NF-E2-related factor 2, is an independent prognostic factor for disease recurrence and reduced survival in stage I non-small cell lung cancer. Clin. Cancer Res. 2007, 13:3875-3882.
266. Kim Y.J., Ahn J.Y., Liang P., Ip C., Zhang Y., Park Y.M. Human prx1 gene is a target of Nrf2 and is up-regulated by hypoxia/reoxygenation: implication to tumor biology. Cancer Res. 2007, 67:546-554.
267. Persons D.L., Yazlovitskaya E.M., Cui W., Pelling J.C. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin. Cancer Res. 1999, 5:1007-1014.
268. Steinmetz R., Wagoner H.A., Zeng P., Hammond J.R., Hannon T.S., Meyers J.L., Pescovitz O.H. Mechanisms regulating the constitutive activation of the extracellular signal-regulated kinase (ERK) signaling pathway in ovarian cancer and the effect of ribonucleic acid interference for ERK1/2 on cancer cell proliferation. Mol. Endocrinol. 2004, 18:2570-2582.
269. Camps M., Nichols A., Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000, 14:6-16.
270. Keyse S.M. Protein phosphatases and the regulation of mitogen-activated protein kinase signalling. Curr. Opin. Cell Biol. 2000, 12:186-192.
271. Nichols A., Camps M., Gillieron C., Chabert C., Brunet A., Wilsbacher J., Cobb M., Pouyssegur J., Shaw J.P., Arkinstall S. Substrate recognition domains within extracellular signal-regulated kinase mediate binding and catalytic activation of mitogen-activated protein kinase phosphatase-3. J. Biol. Chem. 2000, 275:24613-24621.
272. Kim J.J., Tannock I.F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 2005, 5:516-525.
273. Olivieri G., Bodycote J., Wolff S. Adaptive response of human lymphocytes to low concentrations of radioactive thymidine. Science 1984, 223:594-597.
274. Orlowski R.Z., Baldwin A.S. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med. 2002, 8:385-389.
275. Fan M., Ahmed K.M., Coleman M.C., Spitz D.R., Li J.J. Nuclear factor-kappaB and manganese superoxide dismutase mediate adaptive radioresistance in low-dose irradiated mouse skin epithelial cells. Cancer Res. 2007, 67:3220-3228.
276. Guo G., Yan-Sanders Y., Lyn-Cook B.D., Wang T., Tamae D., Ogi J., Khaletskiy A., Li Z., Weydert C., Longmate J.A., Huang T.T., Spitz D.R., Oberley L.W., Li J.J. Manganese superoxide dismutase-mediated gene expression in radiation-induced adaptive responses. Mol. Cell. Biol. 2003, 23:2362-2378.
277. Li Z., Xia L., Lee L.M., Khaletskiy A., Wang J., Wong J.Y., Li J.J. Effector genes altered in MCF-7 human breast cancer cells after exposure to fractionated ionizing radiation. Radiat. Res. 2001, 155:543-553.
278. Izzo J.G., Malhotra U., Wu T.T., Ensor J., Luthra R., Lee J.H., Swisher S.G., Liao Z., Chao K.S., Hittelman W.N., Aggarwal B.B., Ajani J.A. Association of activated transcription factor nuclear factor kappaB with chemoradiation resistance and poor outcome in esophageal carcinoma. J. Clin. Oncol. 2006, 24:748-754.
279. Sandur S.K., Deorukhkar A., Pandey M.K., Pabon A.M., Shentu S., Guha S., Aggarwal B.B., Krishnan S. Curcumin modulates the radiosensitivity of colorectal cancer cells by suppressing constitutive and inducible NF-kappaB activity. Int. J. Radiat. Oncol. Biol. Phys. 2009, 75:534-542.
280. De Ridder M., Verellen D., Verovski V., Storme G. Hypoxic tumor cell radiosensitization through nitric oxide. Nitric Oxide 2008, 19:164-169.
281. Janssens M.Y., Verovski V.N., Van den Berge D.L., Monsaert C., Storme G.A. Radiosensitization of hypoxic tumour cells by S-nitroso-N-acetylpenicillamine implicates a bioreductive mechanism of nitric oxide generation. Br. J. Cancer 1999, 79:1085-1089.
282. Kimura K., Bowen C., Spiegel S., Gelmann E.P. Tumor necrosis factor-alpha sensitizes prostate cancer cells to gamma-irradiation-induced apoptosis. Cancer Res. 1999, 59:1606-1614.
283. Mitchell J.B., Wink D.A., DeGraff W., Gamson J., Keefer L.K., Krishna M.C. Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 1993, 53:5845-5848.
284. Sersa G., Willingham V., Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int. J. Cancer 1988, 42:129-134.
285. Verovski V.N., Van den Berge D.L., Soete G.A., Bols B.L., Storme G.A. Intrinsic radiosensitivity of human pancreatic tumour cells and the radiosensitising potency of the nitric oxide donor sodium nitroprusside. Br. J. Cancer 1996, 74:1734-1742.
286. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 1997, 3:730-737.
287. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 2003, 100:3983-3988.
288. Collins A.T., Berry P.A., Hyde C., Stower M.J., Maitland N.J. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005, 65:10946-10951.
289. Li C., Heidt D.G., Dalerba P., Burant C.F., Zhang L., Adsay V., Wicha M., Clarke M.F., Simeone D.M. Identification of pancreatic cancer stem cells. Cancer Res. 2007, 67:1030-1037.
290. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., Biffoni M., Todaro M., Peschle C., De Maria R. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
291. Schatton T., Murphy G.F., Frank N.Y., Yamaura K., Waaga-Gasser A.M., Gasser M., Zhan Q., Jordan S., Duncan L.M., Weishaupt C., Fuhlbrigge R.C., Kupper T.S., Sayegh M.H., Frank M.H. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
292. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., Dirks P.B. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
293. Szotek P.P., Pieretti-Vanmarcke R., Masiakos P.T., Dinulescu D.M., Connolly D., Foster R., Dombkowski D., Preffer F., Maclaughlin D.T., Donahoe P.K. Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian inhibiting substance responsiveness. Proc. Natl Acad. Sci. USA 2006, 103:11154-11159.
294. Korkaya H., Wicha M.S. Selective targeting of cancer stem cells: a new concept in cancer therapeutics. BioDrugs 2007, 21:299-310.
295. Diehn M., Cho R.W., Lobo N.A., Kalisky T., Dorie M.J., Kulp A.N., Qian D., Lam J.S., Ailles L.E., Wong M., Joshua B., Kaplan M.J., Wapnir I., Dirbas F.M., Somlo G., Garberoglio C., Paz B., Shen J., Lau S.K., Quake S.R., Brown J.M., Weissman I.L., Clarke M.F. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
296. Baba T., Convery P.A., Matsumura N., Whitaker R.S., Kondoh E., Perry T., Huang Z., Bentley R.C., Mori S., Fujii S., Marks J.R., Berchuck A., Murphy S.K. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
297. Ma S., Lee T.K., Zheng B.J., Chan K.W., Guan X.Y. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008, 27:1749-1758.
298. Rhee H.W., Zhau H.E., Pathak S., Multani A.S., Pennanen S., Visakorpi T., Chung L.W. Permanent phenotypic and genotypic changes of prostate cancer cells cultured in a three-dimensional rotating-wall vessel. In Vitro Cell. Dev. Biol. Anim. 2001, 37:127-140.
299. Thalmann G.N., Anezinis P.E., Chang S.M., Zhau H.E., Kim E.E., Hopwood V.L., Pathak S., von Eschenbach A.C., Chung L.W. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res. 1994, 54:2577-2581.
300. Josson S., Matsuoka Y., Chung L.W., Zhau H.E., Wang R. Tumor-stroma co-evolution in prostate cancer progression and metastasis. Semin. Cell Dev. Biol. 2010, 21:26-32.
301. De Marzo A.M., Nakai Y., Nelson W.G. Inflammation, atrophy, and prostate carcinogenesis. Urol. Oncol. 2007, 25:398-400.
302. Sung S.Y., Hsieh C.L., Law A., Zhau H.E., Pathak S., Multani A.S., Lim S., Coleman I.M., Wu L.C., Figg W.D., Dahut W.L., Nelson P., Lee J.K., Amin M.B., Lyles R., Johnstone P.A., Marshall F.F., Chung L.W. Coevolution of prostate cancer and bone stroma in three-dimensional coculture: implications for cancer growth and metastasis. Cancer Res. 2008, 68:9996-10003.
303. Chung L.W., Baseman A., Assikis V., Zhau H.E. Molecular insights into prostate cancer progression: the missing link of tumor microenvironment. J. Urol. 2005, 173:10-20.
304. Porta C., Larghi P., Rimoldi M., Totaro M.G., Allavena P., Mantovani A., Sica A. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 2009, 214:761-777.
305. Mantovani A., Sica A., Allavena P., Garlanda C., Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum. Immunol. 2009, 70:325-330.
306. Sica A., Bronte V. Altered macrophage differentiation and immune dysfunction in tumor development. J. Clin. Invest. 2007, 117:1155-1166.
307. Balkwill F., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005, 7:211-217.
308. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
309. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
310. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002, 23:549-555.
311. Hiratsuka S., Nakamura K., Iwai S., Murakami M., Itoh T., Kijima H., Shipley J.M., Senior R.M., Shibuya M. MMP9 induction by vascular endothelial growth factor receptor-1 is involved in lung-specific metastasis. Cancer Cell 2002, 2:289-300.
312. Surh Y.J., Kundu J.K., Na H.K., Lee J.S. Redox-sensitive transcription factors as prime targets for chemoprevention with anti-inflammatory and antioxidative phytochemicals. J. Nutr. 2005, 135:2993S-3001S.
313. Virgili F., Marino M. Regulation of cellular signals from nutritional molecules: a specific role for phytochemicals, beyond antioxidant activity. Free Radic. Biol. Med. 2008, 45:1205-1216.